Literature DB >> 27123137

Smad4 inhibits cell migration via suppression of JNK activity in human pancreatic carcinoma PANC-1 cells.

Xueying Zhang1, Junxia Cao1, Yujun Pei1, Jiyan Zhang1, Qingyang Wang1.   

Abstract

Smad4 is a common Smad and is a key downstream regulator of the transforming growth factor-β signaling pathway, in which Smad4 often acts as a potent tumor suppressor and functions in a highly context-dependent manner, particularly in pancreatic cancer. However, little is known regarding whether Smad4 regulates other signaling pathways involved in pancreatic cancer. The present study demonstrated that Smad4 downregulates c-Jun N-terminal kinase (JNK) activity using a Smad4 loss-of-function or gain-of-function analysis. Additionally, stable overexpression of Smad4 clearly affected the migration of human pancreatic epithelioid carcinoma PANC-1 cells, but did not affect cell growth. In addition, the present study revealed that upregulation of mitogen-activated protein kinase phosphatase-1 is required for the reduction of JNK activity by Smad4, leading to a decrease in vascular endothelial growth factor expression and inhibiting cell migration. Overall, the present findings indicate that Smad4 may suppress JNK activation and inhibit the tumor characteristics of pancreatic cancer cells.

Entities:  

Keywords:  JNK; Smad4; cell migration; pancreatic cancer

Year:  2016        PMID: 27123137      PMCID: PMC4840846          DOI: 10.3892/ol.2016.4427

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  33 in total

Review 1.  Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases.

Authors:  Gary L Johnson; Razvan Lapadat
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

2.  Thymosinalpha1 stimulates cell proliferation by activating ERK1/2, JNK, and increasing cytokine secretion in human pancreatic cancer cells.

Authors:  Min Li; Louis W Feurino; Fei Li; Hao Wang; Qihui Zhai; William E Fisher; Changyi Chen; Qizhi Yao
Journal:  Cancer Lett       Date:  2006-07-07       Impact factor: 8.679

3.  Conserved docking site is essential for activation of mammalian MAP kinase kinases by specific MAP kinase kinase kinases.

Authors:  Mutsuhiro Takekawa; Kazuo Tatebayashi; Haruo Saito
Journal:  Mol Cell       Date:  2005-04-29       Impact factor: 17.970

4.  Acceleration of Smad2 and Smad3 phosphorylation via c-Jun NH(2)-terminal kinase during human colorectal carcinogenesis.

Authors:  Hideo Yamagata; Koichi Matsuzaki; Shigeo Mori; Katsunori Yoshida; Yoshiya Tahashi; Fukiko Furukawa; Go Sekimoto; Toshihiko Watanabe; Yoshiko Uemura; Noriko Sakaida; Kazuhiko Yoshioka; Yasuo Kamiyama; Toshihito Seki; Kazuichi Okazaki
Journal:  Cancer Res       Date:  2005-01-01       Impact factor: 12.701

5.  Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999-2007: Results of EUROCARE-5.

Authors:  Côme Lepage; Riccardo Capocaccia; Monika Hackl; Valerie Lemmens; Esther Molina; Daniela Pierannunzio; Milena Sant; Annalisa Trama; Jean Faivre
Journal:  Eur J Cancer       Date:  2015-09-26       Impact factor: 9.162

6.  Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.

Authors:  Minoru Oshima; Keiichi Okano; Shinobu Muraki; Reiji Haba; Takashi Maeba; Yasuyuki Suzuki; Shinichi Yachida
Journal:  Ann Surg       Date:  2013-08       Impact factor: 12.969

7.  Role of mitogen-activated protein kinase phosphatase during the cellular response to genotoxic stress. Inhibition of c-Jun N-terminal kinase activity and AP-1-dependent gene activation.

Authors:  Y Liu; M Gorospe; C Yang; N J Holbrook
Journal:  J Biol Chem       Date:  1995-04-14       Impact factor: 5.157

8.  Loss of SMAD4 from colorectal cancer cells promotes CCL15 expression to recruit CCR1+ myeloid cells and facilitate liver metastasis.

Authors:  Yoshiro Itatani; Kenji Kawada; Teruaki Fujishita; Fumihiko Kakizaki; Hideyo Hirai; Takuya Matsumoto; Masayoshi Iwamoto; Susumu Inamoto; Etsuro Hatano; Suguru Hasegawa; Taira Maekawa; Shinji Uemoto; Yoshiharu Sakai; Makoto Mark Taketo
Journal:  Gastroenterology       Date:  2013-07-25       Impact factor: 22.682

Review 9.  Molecular classification of neoplasms of the pancreas.

Authors:  Ralph H Hruban; N Volkan Adsay
Journal:  Hum Pathol       Date:  2009-05       Impact factor: 3.466

10.  SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.

Authors:  Amanda Blackford; Oscar K Serrano; Christopher L Wolfgang; Giovanni Parmigiani; Siân Jones; Xiaosong Zhang; D Williams Parsons; Jimmy Cheng-Ho Lin; Rebecca J Leary; James R Eshleman; Michael Goggins; Elizabeth M Jaffee; Christine A Iacobuzio-Donahue; Anirban Maitra; John L Cameron; Kelly Olino; Richard Schulick; Jordan Winter; Joseph M Herman; Daniel Laheru; Alison P Klein; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Ralph H Hruban
Journal:  Clin Cancer Res       Date:  2009-07-07       Impact factor: 12.531

View more
  8 in total

1.  SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells.

Authors:  Hiroyuki Ozawa; Ruchira S Ranaweera; Evgeny Izumchenko; Eugene Makarev; Alex Zhavoronkov; Elana J Fertig; Jason D Howard; Ana Markovic; Atul Bedi; Rajani Ravi; Jimena Perez; Quynh-Thu Le; Christina S Kong; Richard C Jordan; Hao Wang; Hyunseok Kang; Harry Quon; David Sidransky; Christine H Chung
Journal:  Clin Cancer Res       Date:  2017-05-18       Impact factor: 12.531

Review 2.  JNK signaling as a target for anticancer therapy.

Authors:  Kamal S Abdelrahman; Heba A Hassan; Salah A Abdel-Aziz; Adel A Marzouk; Atsushi Narumi; Hiroyuki Konno; Mohamed Abdel-Aziz
Journal:  Pharmacol Rep       Date:  2021-03-12       Impact factor: 3.024

3.  miR-146a promotes cell migration and invasion in melanoma by directly targeting SMAD4.

Authors:  Wei Pu; Yongming Shang; Qiang Shao; Xinpeng Yuan
Journal:  Oncol Lett       Date:  2018-03-05       Impact factor: 2.967

4.  The Role of Platelet-Derived ADP and ATP in Promoting Pancreatic Cancer Cell Survival and Gemcitabine Resistance.

Authors:  Omar Elaskalani; Marco Falasca; Niamh Moran; Michael C Berndt; Pat Metharom
Journal:  Cancers (Basel)       Date:  2017-10-24       Impact factor: 6.639

5.  Upregulation of miR-146a-5p is associated with increased proliferation and migration of vascular smooth muscle cells in aortic dissection.

Authors:  Ling Xue; Songyuan Luo; Huanyu Ding; Yuan Liu; Wenhui Huang; Xiaoping Fan; Min Wu; Xuhua Jian; Cheng Huang; Jianfang Luo; Ruixin Fan
Journal:  J Clin Lab Anal       Date:  2019-02-19       Impact factor: 2.352

6.  SMAD4 Y353C promotes the progression of PDAC.

Authors:  Zusen Wang; Yongxing Li; Shixiong Zhan; Lu Zhang; Shun Zhang; Qian Tang; Miaomiao Li; Zhen Tan; Shiguo Liu; Xiaoming Xing
Journal:  BMC Cancer       Date:  2019-11-04       Impact factor: 4.430

Review 7.  SMAD4 and the TGFβ Pathway in Patients with Pancreatic Ductal Adenocarcinoma.

Authors:  Julie Dardare; Andréa Witz; Jean-Louis Merlin; Pauline Gilson; Alexandre Harlé
Journal:  Int J Mol Sci       Date:  2020-05-16       Impact factor: 5.923

8.  TMEFF2 inhibits pancreatic cancer cells proliferation, migration, and invasion by suppressing phosphorylation of the MAPK signaling pathway.

Authors:  Hongchao Han; Zhilin Zhan; Jie Xu; Zhenshun Song
Journal:  Onco Targets Ther       Date:  2019-12-23       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.